Drug Details

General Information of the Drug (ID: DR6719)
Name
Lincomycin
Synonyms
lincomycin; 154-21-2; Cillimycin; Lincomycinum; Lincomicina; Lincomycin A; Lincomycin hydrochloride; UNII-BOD072YW0F; CHEMBL1447; Lincolnensin; Lincomycine; Jiemycin; Lincocin; Lincomycin (USAN/INN); BOD072YW0F; U 10,149A; CHEBI:6472; Frademicina; (2S,4R)-N-((1R,2R)-2-hydroxy-1-((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)propyl)-1-methyl-4-propylpyrrolidine-2-carboxamide; U-10149; Methyl 6,8-dideoxy-6-trans-(1-methyl-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-D-erythro-alpha-D-galacto-octopyranoside; U-10,149; LCM; (2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide; (2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyl-tetrahydropyran-2-yl]propyl]-1-methyl-4-propyl-pyrrolidine-2-carboxamide; methyl 6,8-dideoxy-6-{[(4R)-1-methyl-4-propyl-L-prolyl]amino}-1-thio-D-erythro-alpha-D-galacto-octopyranoside; Lincomycin, (2S-cis)-Isomer; Lincomycine [French]; C18H34N2O6S; NSC-70731; AC1MHD7X; Lincomycine [INN-French]; Lincomycinum [INN-Latin]; Lincomicina [INN-Spanish]; Bactramycin; Lincorex; Lincomycin [USAN:INN:BAN]; HSDB 3109; L-Mycin; Lincomycin,(S); 3QB; EINECS 205-824-6; NSC70731; BRN 0707677; SCHEMBL4010; D-erythro-alpha-D-galacto-Octopyranoside, methyl 6,8-dideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, (2S-trans)-; DTXSID3023215; GTPL10941; HMS2089A13; ZINC3982483; BDBM50335522; AKOS015951392; CCG-208231; DB01627; MCULE-4676929559; NE39438; SMP1_000178; (2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide; D-erythro-D-galacto-Octopyranoside, methyl 6,8-dideoxy-6-(1-methyl-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-, trans-alpha-; Methyl 6,8-dideoxy-6-(1-methyl-4-propyl-2-pyrrolidinecarboxamido)-1-thio-D-erythro-D-galacto-octopyranoside (alpha-form); 54L212; C06812; D00223; AB01275426-01; Lincomycin, Antibiotic for Culture Media Use Only; Q423428; W-109518; BRD-K49384696-003-01-9; Z1665194511; (2S,4R)-N-((1R,2R)-2-hydroxy-1-((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)-tetrahydro-2H-pyran-2-yl)propyl)-1-methyl-4-propylpyrrolidine-2-carboxamide; (2S,4R)-N-((1S)-2-hydroxy-1-((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)-tetrahydro-2H-pyran-2-yl)propyl)-1-methyl-4-propylpyrrolidine-2-carboxamide; 1-Methyl-4-propyl-pyrrolidine-2-carboxylic acid [2-hydroxy-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; D-Erythro-.alpha.-D-gluco-octopyranoside, methyl 6,8-dideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-; D-erythro-alpha-D-galacto-Octopyranoside, methyl 6,8-dideoxy-6-((((2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-; Methyl (5r)-5-[(1r,2r)-2-Hydroxy-1-{[(4r)-1-Methyl-4-Propyl-L-Prolyl]amino}propyl]-1-Thio-Beta-L-Arabinopyranoside; methyl 6,8-dideoxy-6-({[(2S,4R)-1-methyl-4-propylpyrrolidin-2-yl]carbonyl}amino)-1-thio-D-erythro-alpha-D-galacto-octopyranoside
    Click to Show/Hide
Molecular Type
Small molecule
Disease Bacterial infection [ICD-11: 1A00-1C4Z] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C18H34N2O6S
PubChem CID
3000540
Canonical SMILES
CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)O
InChI
1S/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9-,10-,11+,12-,13+,14-,15-,16-,18-/m1/s1
InChIKey
OJMMVQQUTAEWLP-KIDUDLJLSA-N
CAS Number
CAS 154-21-2
ChEBI ID
CHEBI:6472
TTD Drug ID
D0Q0EX
DrugBank ID
DB01627
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Caffeic acid + Chitosan     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Propionibacterium acnes KCTC 3314 Microorganism model Propionibacterium acnes
Staphylococcus aureus KCTC 1927 Microorganism model Staphylococcus aureus
Staphylococcus epidermidis KCTC 1370 Microorganism model Staphylococcus epidermidis
Pseudomonas aeruginosa KCTC 1637 Microorganism model Pseudomonas aeruginosa
                    Experimental
                    Result(s)		 Among chitosan-conjugated derivatives, Chitosan-caffeic acid showed the highest antibacterial activity and also exhibited the synergistic antibacterial effect in combination with tetracycline, erythromycin, and lincomycin against acne-related bacteria.
Target and Pathway
Target(s) Bacterial 50S ribosomal RNA (Bact 50S rRNA)  Molecule Info  [3]
References
Reference 1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050317.
Reference 2 Synergistic Antibacterial Effects of Chitosan-Caffeic Acid Conjugate against Antibiotic-Resistant Acne-Related Bacteria. Mar Drugs. 2017 Jun 8;15(6):167.
Reference 3 Specific inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics. Curr Microbiol. 2000 Aug;41(2):126-35.
 Download Picture         KEGG Link